**Supplementary Table 2: features of patients with hepatocholangiocarcinoma treated by platinum-based chemotherapy versus tyrosine kinase inhibitors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Data available** | **Platinum Based Chemotherapy (n=54)** | **Tyrosine Kinase Inhibitors (N=25)** | **P-value** |
| Male\* | 79 | 37 (68.5) | 20 (80.0) | 0.430 |
| Age (years old)% | 79 | 63.53 [57.34, 71.69] | 62.03 [54.93, 68.90] | 0.337 |
| Hepatitis B virus\* | 74 | 10 (18.9) | 5 (23.8) | 0.876 |
| Hepatitis C virus\* | 73 | 11 (20.8) | 4 (20.0) | 1.000 |
| Metabolic syndrome\* | 71 | 23 (47.9) | 9 (39.1) | 0.659 |
| Tobacco use\* | 73 | 28 (54.9) | 13 (59.1) | 0.941 |
| Chronic alcohol intake\* | 73 | 22 (44.9) | 12 (50.0) | 0.872 |
| Body mass index% | 77 | 23.50 [21.46, 27.00] | 24.00 [21.00, 27.07] | 0.813 |
| Diabetes type 2\* | 74 | 20 (40.0) | 9 (37.5) | 1.000 |
| Arterial hypertension\* | 76 | 28 (53.8) | 11 (45.8) | 0.687 |
| Dyslipidemia\* | 74 | 23 (46.0) | 9 (37.5) | 0.660 |
| Performance status 0/1\* | 63 | 38 (82.6) | 15 (88.2) | 0.480 |
| Advanced fibrosis/cirrhosis (F3-F4)\* | 71 | 25 (52.1) | 14 (60.9) | 0.659 |
| Child Pugh A% | 30 | 16 (76.1) | 6 (66.7) | 0.677 |
| **Biochemical characteristics** | | | | |
| Aspartate transaminase% | 73 | 1.10 [1.00, 1.55] | 1.00 [0.67, 1.47] | 0.108 |
| Alanine transaminase% | 72 | 1.00 [0.60, 1.40] | 0.94 [0.60, 1.00] | 0.208 |
| Alkaline phosphatase% | 70 | 1.20 [0.81, 2.52] | 1.00 [0.85, 1.30] | 0.336 |
| Gamma glutamyl transferase% | 72 | 2.62 [1.23, 6.58] | 2.70 [2.00, 5.00] | 0.954 |
| Total bilirubin µmol/l% | 75 | 11.00 [7.00, 14.50] | 14.00 [10.00, 19.50] | 0.124 |
| Albumin g/l% | 66 | 36.50 [32.00, 41.25] | 34.00 [31.00, 37.00] | 0.170 |
| Time of prothrombin (%)% | 69 | 86.00 [78.00, 95.00] | 87.00 [76.25, 97.75] | 0.959 |
| Platelets G/l% | 74 | 213.00 [176.50, 297.50] | 181.00 [135.50, 267.00] | 0.073 |
| Creatinine µmol/l% | 71 | 66.00 [60.25, 78.00] | 70.00 [60.00, 87.00] | 0.484 |
| Serum AFP% | 60 | 6.50 [1.00, 44.25] | 17.65 [1.00, 124.25] | 0.610 |
| Serum CA 19-9% | 46 | 5.05 [1.38, 45.00] | 1.00 [1.00, 1.32] | 0.035 |
| MELD score% | 71 | 8.00 [7.00, 10.00] | 9.50 [8.00, 11.00] | 0.239 |
| ALBI score% | 60 | -2.49 [-2.84, -2.04] | -1.98 [-2.34, -1.88] | 0.037 |
| **Tumor characteristics** | | | | |
| Multiple intrahepatic lesions\* | 73 | 20 (39.2) | 7 (31.8) | 0.736 |
| Macrovascular invasion\* | 72 | 17 (32.7) | 6 (27.3) | 0.853 |
| Metastatic disease\* | 76 | 32 (60.4) | 19 (82.6) | 0.103 |
| Size of biggest nodule (mm)% | 68 | 54.00 [30.00, 82.50] | 40.00 [20.00, 85.00] | 0.661 |

\*n(%)

% median (interquartile range)

The % of Child pugh A patient was calculated on advanced fibrosis/cirrhosis patients

AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; MELD, Model for End-Stage Liver Disease; ALBI, albumin-bilirubin

CA19-9, AFP are represented as times above normal (median [IQR])